GGrantIndex
Sort

51,593 grants matching hepatitis

GENETICALLY MODIFIED HEPATOCYTES TO ACHIEVE SUCCESS IN LIVER CELL TRANSPLANTATION

$613,378
David A Shafritz · Albert Einstein College Of Medicine, Inc · R01 · FY2015 · DK

Biochemistry of Protein Prenylation

$613,376
Michael H Gelb · University Of Washington · R01 · FY2011 · AI

Mechanisms of hepatic innate immune activation by HCV

$613,337
Michael J Gale · University Of Washington · R01 · FY2018 · AI

Core 1: Administrative Core

$613,316
Bruce R Schackman · Weill Medical Coll Of Cornell Univ · P30 · FY2021 · DA

Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis

$613,306
Donald W. Kufe · Dana-Farber Cancer Inst · U01 · FY2008 · CA

Role of the innate immune defenses in viral infections

$613,270
Barbara Rehermann · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2010 · DK

Lipogenesis, lipoprotein flux & CVD risk: role of meal composition & frequency

$613,174
Jean-Marc Schwarz · Touro University Of California · R01 · FY2016 · HL

Isolation, characterization, and transplantation of candidate stem cells

$613,083
John Tisdale · National Heart, Lung, And Blood Institute · ZIA · FY2011 · HL

Brief Intervention for Drug Misuse for the Emergency Department (BIDMED)

$613,045
Roland C Merchant · Rhode Island Hospital · R01 · FY2012 · DA

Combination Gene Therapy for Treatment of Canine Mucopolysaccharidosis Type I

$613,028
Raymond Yu Jeang Wang · Children'S Hospital Of Orange County · R01 · FY2024 · HD

Implementation science research on PrEP delivery and costing within MAT and NSP services for PWUD in Uganda

$613,015
Renee A. Heffron · University Of Washington · R01 · FY2021 · DA

Molecular pathogenesis of blastomycosis

$612,804
Bruce Steven Klein · University Of Wisconsin-Madison · R37 · FY2025 · AI

Developmental Funds

$612,636
Scott M Lippman · University Of California, San Diego · P30 · FY2019 · CA

Molecular and Cellular Basis of PCB Developmental Neurotoxicity

$612,589
Pamela J Lein · University Of California At Davis · R01 · FY2022 · ES

Improving Hepatitis C Treatment in Injection Drug Users

$612,502
Upstate Medical University · R01 · FY2003 · DA

Biochemical and Genetic Markers of Type 2 Diabetes Risk

$612,499
Frank B Hu · Brigham And Women'S Hospital · R01 · FY2012 · DK

In search of an HBV cure: novel model systems and targets

$612,444
Charles M. Rice · Rockefeller University · R01 · FY2019 · AI

Investigation of management and disease manifestations of viral hepatitis

$612,410
Theo Heller · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2018 · DK

Investigation of management and disease manifestations of viral hepatitis

$612,410
Theo Heller · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2017 · DK

Investigation of management and disease manifestations of viral hepatitis

$612,410
Theo Heller · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2016 · DK

NEW PROBE AND METHODS FOR CORRELATED LM AND EM

$612,403
Roger Y Tsien · University Of California, San Diego · R01 · FY2014 · GM

Simulation Modeling to Improve HIV/HCV Screening, Treatment and Care

$612,390
Benjamin P Linas · Boston Medical Center · R01 · FY2015 · DA

Psychoeducation for HCV and Alcohol Behaviors

$612,314
Carol S North · Ut Southwestern Medical Center · R01 · FY2006 · AA

Disease Management for Chronic Drug Abuse

$612,241
Jon Morgenstern Morgenstern · Partnership To End Addiction · R01 · FY2011 · DA

HIV-1 Preintegration Trafficking and Nuclear Localization

$612,217
Alan N. Engelman · Dana-Farber Cancer Inst · R01 · FY2024 · AI